AQUESTIVE THERAPEUTICS INC (AQST) Stock Price, Forecast & Analysis

USA Nasdaq NASDAQ:AQST • US03843E1047

4.11 USD
+0.27 (+7.03%)
At close: Feb 6, 2026
4.08 USD
-0.03 (-0.73%)
After Hours: 2/6/2026, 8:18:05 PM

AQST Key Statistics, Chart & Performance

Key Statistics
Market Cap501.42M
Revenue(TTM)43.40M
Net Income(TTM)-68.92M
Shares122.00M
Float112.33M
52 Week High7.55
52 Week Low2.12
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.71
PEN/A
Fwd PEN/A
Earnings (Next)03-03
IPO2018-07-25
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
AQST short term performance overview.The bars show the price performance of AQST in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20

AQST long term performance overview.The bars show the price performance of AQST in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300 400

The current stock price of AQST is 4.11 USD. In the past month the price decreased by -33.82%. In the past year, price increased by 38.85%.

AQUESTIVE THERAPEUTICS INC / AQST Daily stock chart

AQST Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to AQST. When comparing the yearly performance of all stocks, AQST turns out to be only a medium performer in the overall market: it outperformed 49.46% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

AQST Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to AQST. AQST may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AQST Financial Highlights

Over the last trailing twelve months AQST reported a non-GAAP Earnings per Share(EPS) of -0.71. The EPS decreased by -61.36% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -42.14%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-7.69%
Sales Q2Q%-5.43%
EPS 1Y (TTM)-61.36%
Revenue 1Y (TTM)-26.32%

AQST Forecast & Estimates

15 analysts have analysed AQST and the average price target is 9.29 USD. This implies a price increase of 126.11% is expected in the next year compared to the current price of 4.11.

For the next year, analysts expect an EPS growth of -26.94% and a revenue growth -23.71% for AQST


Analysts
Analysts84
Price Target9.29 (126.03%)
EPS Next Y-26.94%
Revenue Next Year-23.71%

AQST Ownership

Ownership
Inst Owners53.88%
Ins Owners4.5%
Short Float %18.07%
Short Ratio3.87

AQST Latest News, Press Relases and Analysis

AQST Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
LLY ELI LILLY & CO31.531T
JNJ JOHNSON & JOHNSON20.6578.208B
MRK MERCK & CO. INC.22.54302.633B
PFE PFIZER INC9.06154.765B
BMY BRISTOL-MYERS SQUIBB CO10.19126.196B
ZTS ZOETIS INC18.5556.153B
RPRX ROYALTY PHARMA PLC- CL A8.6125.774B
VTRS VIATRIS INC5.7616.793B
ELAN ELANCO ANIMAL HEALTH INC24.112.521B
AXSM AXSOME THERAPEUTICS INC222.919.202B

About AQST

Company Profile

AQST logo image Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 142 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. The company has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The firm also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The firm is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.

Company Info

AQUESTIVE THERAPEUTICS INC

30 Technology Dr

WARREN NEW JERSEY 07059 US

CEO: Keith J. Kendall

Employees: 142

AQST Company Website

AQST Investor Relations

Phone: 19089411900

AQUESTIVE THERAPEUTICS INC / AQST FAQ

What does AQST do?

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 142 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. The company has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The firm also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The firm is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.


What is the current price of AQST stock?

The current stock price of AQST is 4.11 USD. The price increased by 7.03% in the last trading session.


Does AQUESTIVE THERAPEUTICS INC pay dividends?

AQST does not pay a dividend.


How is the ChartMill rating for AQUESTIVE THERAPEUTICS INC?

AQST has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Can you provide the growth outlook for AQUESTIVE THERAPEUTICS INC?

The Revenue of AQUESTIVE THERAPEUTICS INC (AQST) is expected to decline by -23.71% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


What is the market capitalization of AQST stock?

AQUESTIVE THERAPEUTICS INC (AQST) has a market capitalization of 501.42M USD. This makes AQST a Small Cap stock.


Who owns AQUESTIVE THERAPEUTICS INC?

You can find the ownership structure of AQUESTIVE THERAPEUTICS INC (AQST) on the Ownership tab.